Avatrombopag Treatment of Severe Aplastic Anemia With Liver Injury: a Case Report

Abstract At present, avatrombopag has not obtained a clinical license and is not accepted as a standard clinical treatment of Severe aplastic anemia. Here, We present a case of SAA treated with avatrombopag. Our patient was intolerant to eltrombopag, demonstrating elevated transaminase levels, but avatrombopag treatment was well tolerated with high effectiveness. Therefore, avatrombopag may not cause hepatotoxicity compared with other TPO receptor agonist for SAA treatment, and its combination with CsA may be a possible safe and effective treatment for long-term SAA management. Our case highlights the importance of recognizing TPO-RAS as a safe and effective treatment of SAA and adds avatrombopag to this list.